Business Context and Reporting Period
This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) for the reporting period of April 6, 2009. The filing addresses a material modification to the rights of security holders regarding the company's 6% Convertible Exchangeable Preferred Stock.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the suspension of a scheduled dividend payment.
Material Changes
- Dividend Suspension: The Board of Directors resolved to suspend the quarterly cash dividend on the Preferred Stock scheduled for May 1, 2009.
- Accrual of Dividends: Unpaid dividends will accrue.
- Governance Consequence: If the company fails to pay an aggregate amount equal to at least six quarterly dividends (consecutive or not), the Board of Directors will increase by two members. Holders of the Preferred Stock will gain the right to vote separately as a class to fill these vacancies until all accrued dividends are paid.
Outlook and Management Commentary
Management stated that the Board of Directors will continue to evaluate the payment of a quarterly cash dividend on a quarterly basis. A press release announcing this suspension was issued on April 8, 2009.
Investor Verification Checklist
- Verify the total amount of accrued but unpaid dividends on the 6% Convertible Exchangeable Preferred Stock.
- Confirm the current number of quarterly dividend payments missed to assess the proximity to the six-payment threshold that triggers board expansion.
- Review the company's cash position in subsequent filings to determine the likelihood of resuming dividend payments.
- Check for any amendments to the Preferred Stock indenture regarding the suspension terms.